{"id":"topotecan-dexamethasone-vincristine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea"},{"rate":"40-60%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Topotecan works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication and repair. Vincristine, on the other hand, binds to tubulin and prevents the formation of microtubules, which are essential for cell division. Dexamethasone, a synthetic corticosteroid, has anti-inflammatory and immunosuppressive properties, which can help reduce swelling and inflammation in the body.","oneSentence":"Topotecan is a topoisomerase I inhibitor, vincristine is a vinca alkaloid that disrupts microtubule formation, and dexamethasone is a corticosteroid that suppresses inflammation and immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:22.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia, Small cell lung cancer, Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143},{"nctId":"NCT00187083","phase":"PHASE3","title":"A Study of Children With Refractory or Relapsed ALL","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1997-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topotecan, dexamethasone, vincristine","genericName":"Topotecan, dexamethasone, vincristine","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topotecan is a topoisomerase I inhibitor, vincristine is a vinca alkaloid that disrupts microtubule formation, and dexamethasone is a corticosteroid that suppresses inflammation and immune response. Used for Acute lymphoblastic leukemia, Small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}